FDA Clears Gen-Probe's PANTHER System For Use With APTIMA Combo 2 Assay

5/8/2012 8:09 AM ET

Gen-Probe Inc. (GPRO: Quote) Tuesday said the US Food and Drug Administration has cleared its PANTHER system, a fully automated and integrated molecular testing platform designed with the flexibility to handle a wide range of testing needs.

The PANTHER system can initially be used to test for the common sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae with the APTIMA Combo 2 assay.

According to the company, using this system, a single operator can process 275 samples in eight hours.

Gen-Probe will begin shipments of PANTHER systems to US customers during the second quarter.

Click here to receive FREE breaking news email alerts for Gen-Probe Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 72 Articles

Editors Pick

BoJ Keeps Easing Plan Intact; Upgrades Economic View

The Bank of Japan on Wednesday decided to keep its ultra-loose monetary policy unchanged, as expected, suggesting that the bank is moving cautiously amid concerns over the recent turmoil in the bond market. The policy board said the bank will conduct money market operations so that the monetary base will increase at an annual pace of about JPY 60-70 trillion.

Australia Consumer Morale Falls Sharply On Budget

Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012.

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.